2 Hrs
Source:
المشهد
Ipsen drug shows promise
A clinical trial involving 92 patients with primary biliary cholangitis found that Ipsen’s drug Iqirvo improved alkaline phosphatase levels in patients who had not responded adequately to standard treatment. After 12 months, enzyme levels had returned to normal in 85.3% of patients taking the drug, compared with 23.3% in the placebo group; average levels fell by 36.5%, compared with 4.2%. Although other measures of liver function also improved, researchers cautioned that laboratory results alone do not prove the drug slows disease progression or relieves symptoms.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)